Shares of Allergy Therapeutics plc (LON:AGY – Get Free Report) reached a new 52-week low on Tuesday. The stock traded as low as GBX 4.50 and last traded at GBX 5, with a volume of 288,979 shares. The stock had previously closed at GBX 4.75.
Allergy Therapeutics Stock Up 5.3%
The stock’s 50-day moving average is GBX 5.15 and its 200-day moving average is GBX 7.40. The stock has a market cap of £316.63 million, a P/E ratio of -5.15, a price-to-earnings-growth ratio of -30.70 and a beta of 0.83. The company has a current ratio of 1.13, a quick ratio of 1.48 and a debt-to-equity ratio of 629.58.
Allergy Therapeutics Company Profile
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.
Further Reading
- Five stocks we like better than Allergy Therapeutics
- Could T-Mobile’s Satellite Competition Fears Create a Buying Opportunity?
- Surgical Precision, Sustainable Returns: Johnson & Johnson Secures its Cash Flow Runway
- Tesla’s Robotaxi Lands in Paris—But Europe’s Real Fight Is Over Cheap EVs
- IonQ Fell 9% on a $1.3 Billion Deal—Is Wall Street Missing Something?
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
